Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by PNPLA3 is a triacylglycerol lipase that mediates triacylglycerol hydrolysis in adipocytes. Additionally we are shipping PNPLA3 Kits (14) and PNPLA3 Proteins (7) and many more products for this protein.
Showing 10 out of 89 products:
Human Polyclonal PNPLA3 Primary Antibody for EIA, WB - ABIN954228
Santoro, Kursawe, DAdamo, Dykas, Zhang, Bale, Calí, Narayan, Shaw, Pierpont, Savoye, Lartaud, Eldrich, Cushman, Zhao, Shulman, Caprio: A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. in Hepatology (Baltimore, Md.) 2010
Show all 3 references for ABIN954228
Human Polyclonal PNPLA3 Primary Antibody for IHC, ELISA - ABIN361184
Kumari, Schoiswohl, Chitraju, Paar, Cornaciu, Rangrez, Wongsiriroj, Nagy, Ivanova, Scott, Knittelfelder, Rechberger, Birner-Gruenberger, Eder, Brown, Haemmerle, Oberer, Lass, Kershaw, Zimmermann et al.: Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. ... in Cell metabolism 2012
Show all 2 references for ABIN361184
Human Polyclonal PNPLA3 Primary Antibody for IHC, WB - ABIN2783569
Wilson, Gardner, Lambie, Commans, Crowther: Characterization of the human patatin-like phospholipase family. in Journal of lipid research 2006
Human Polyclonal PNPLA3 Primary Antibody for ELISA, IHC - ABIN4278479
Steinberg, Kemp, Watt: Adipocyte triglyceride lipase expression in human obesity. in American journal of physiology. Endocrinology and metabolism 2007
This is the first study to report the interaction between the PNPLA3 rs738409 polymorphism and physical activity or sedentary behavior on Non-Alcoholic Fatty Liver Disease, providing new clues on the function of the PNPLA3 gene
Data show that the alleles of PNPLA3 locus with differential distribution in cohorts with non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH (show SAMSN1 Antibodies)) and pericellular fibrosis. Heterozygosity at this locus is independently associated with higher risk of having NASH (show SAMSN1 Antibodies) and pericellular fibrosis.
In NAFLD (show TSC2 Antibodies) patients, carriage of the PNPLA3G allele, and particularly of the GG genotype, is significantly associated with the risk of cirrhotic evolution
The hepatic copper content and PNPLA3 mutations are associated with disease activity in NAFLD (show TSC2 Antibodies) patients without MetS (show ETV3 Antibodies). Presence of MetS (show ETV3 Antibodies) appears to mask the effects of hepatic copper and PNPLA3.
Among Mexicans, the PNPLA3 (rs738409), LYPLAL1 (show LYPLAL1 Antibodies) (rs12137855), PPP1R3B (show PPP1R3B Antibodies) (rs4240624), and GCKR (show GCKR Antibodies) (rs780094) polymorphisms may be associated with a greater risk of chronic liver disease among overweight adults.
SNPs rs2896019 and rs3810622 significantly associated with increased risk of nonalcoholic fatty liver disease in Han Chinese population
The PNPLA3 148 I/M or M/M variants and CD4 (show CD4 Antibodies)(+) cell count were the only independent predictors of severe steatosis in patients with hepatitis C virus non-3 genotypes.
the PNPLA3 rs738409 was determined to be associated with hepatocellular carcinoma development in a cohort of Japanese patients with type 2 diabetes mellitus
PNPLA3 p.I148M variant represents the most important prosteatotic genetic risk factor. NAFLD (show TSC2 Antibodies) carriers of this variant should be followed up carefully, with elastography being ideally suited for this purpose.
The PNPLA3 p.I148M variant is associated with non-alcoholic fatty liver disease.
Neither ablation nor overexpression of wild-type PNPLA3 affects liver fat content in mice, whereas hepatic overexpression of the human 148M transgene causes steatosis.
PNPLA3 plays a role in remodeling TAG in lipid droplets, as they accumulate in response to food intake
adiponutrin/PNPLA3 is regulated by two key factors of the glycolytic and lipogenic pathways, raising the question of its implication in the metabolism of carbohydrates and lipids
data argue against a role for Pnpla3 loss-of-function in fatty liver disease or metabolic syndrome in mice.
Loss of Pnpla3 does not cause fatty liver, liver enzyme elevation, or insulin (show INS Antibodies) resistance in mice.
Microarray-based gene profiling showed that the expression level of PNPLA3 in hepatocytes is correlated with that of genes associated with the lipogenic pathway such as ME1 (show ME1 Antibodies), SPOT14 (show THRSP Antibodies), and SCD1 (show SCD Antibodies).
data suggest that murine ATGL (show PNPLA2 Antibodies) but not adiponutrin contributes to net adipocyte lipolysis and that ATGL (show PNPLA2 Antibodies) and adiponutrin are oppositely regulated by insulin (show INS Antibodies) both in vitro and in vivo
The protein encoded by this gene is a triacylglycerol lipase that mediates triacylglycerol hydrolysis in adipocytes. The encoded protein, which appears to be membrane bound, may be involved in the balance of energy usage/storage in adipocytes.
, calcium-independent phospholipase A2-epsilon
, patatin-like phospholipase domain-containing protein 3